A Phase II Study of Combine Modality Therapy in Locally Advanced Pancreatic Cancer
Status:
Unknown status
Trial end date:
2008-10-01
Target enrollment:
Participant gender:
Summary
Induction chemotherapy will be administered every 2 weeks for 6 cycles (about 3 months).
Patients who have radiological evidence of progressive disease will be shifted to salvage
chemotherapy. Patients who have responsive or stable disease after induction chemotherapy
will receive concurrent chemoradiotherapy 3-4 weeks after the last dose of induction
chemotherapy. Surgical evaluation will be performed 4-6 weeks after the completion of
chemoradiotherapy. Patients who have resectable disease will undergo surgical resection.
Postoperative adjuvant chemotherapy with GOFL for 6 cycles will be given for those who have
curative resection. Patients who still have unresectable disease or non-curative resection
will receive systemic chemotherapy of GOFL till disease progression or unacceptable toxicity.
Phase:
Phase 2
Details
Lead Sponsor:
National Health Research Institutes, Taiwan
Collaborators:
Chang Gung Memorial Hospital China Medical University Hospital Mackay Memorial Hospital National Cheng-Kung University Hospital National Taiwan University Hospital